European Navenibart Deal: A Strategic Win for BioCryst's Rare Disease Portfolio

Key Takeaways

• BioCryst received $70 million upfront and up to $275 million in milestones from Neopharmed Gentili for European rights to Navenibart, per an SEC Form 8-K filing.
• Navenibart is a long-acting monoclonal antibody targeting plasma kallikrein, currently in two Phase 3 trials: ALPHA-ORBIT (NCT06842823) and ORBIT-EXPANSE (NCT07204938) listed on ClinicalTrials.gov.
• BioCryst acquired Navenibart through its $700 million merger with Astria Therapeutics completed October 2025.
• The deal includes tiered royalties of 18% to 30% on European net sales, with BioCryst retaining full U.S. commercial rights.
• BioCryst expects to file for regulatory approval by end of 2027 based on Phase 3 data.

What are the financial terms of the Navenibart deal?

The agreement delivers $70 million in upfront cash to BioCryst. This immediate payment strengthens BioCryst's balance sheet as it advances Navenibart through Phase 3 development. The deal also includes performance-based milestone payments totaling up to $275 million. These milestones tie to regulatory approvals and sales achievements in European markets.

BioCryst will receive tiered royalties ranging from 18% to 30% on net European sales once Navenibart launches. This structure aligns both parties toward commercial success. Neopharmed Gentili gains exclusive rights to market Navenibart across Europe. This partnership builds on an earlier 2025 transaction where Neopharmed acquired BioCryst's European Orladeyo business.

How does Navenibart fit into BioCryst's HAE portfolio?

Navenibart offers a differentiated mechanism for HAE prophylaxis. The drug is a long-acting monoclonal antibody that inhibits plasma kallikrein. This target sits at the center of HAE pathophysiology. By blocking plasma kallikrein, Navenibart prevents the bradykinin-driven swelling attacks that characterize the disease.

The drug's extended half-life supports less frequent dosing. Phase 3 trials are evaluating quarterly and semi-annual administration schedules. This profile contrasts with Orladeyo, BioCryst's approved oral daily therapy. Together, these assets give physicians options across the treatment spectrum.

BioCryst acquired Navenibart through its merger with Astria Therapeutics. The $700 million transaction closed in October 2025. It brought Navenibart (formerly STAR-0215) into BioCryst's pipeline as a Phase 3-ready program.

What do we know about the Phase 3 clinical program?

Two ongoing trials support Navenibart's development. The ALPHA-ORBIT study (NCT06842823) is a randomized, double-blind, placebo-controlled trial. It enrolls adults and adolescents with HAE Type 1 or Type 2. Participants receive either Navenibart or placebo across multiple dosing arms. The primary endpoint measures reduction in HAE attack frequency. This trial targets primary completion in March 2027.

The ORBIT-EXPANSE study (NCT07204938) provides long-term safety and efficacy data. This extension trial accepts participants who completed ALPHA-ORBIT. It uses a two-part design with dose-controlled and personalized dosing phases. The study runs through 2031, generating comprehensive long-term data for regulators and clinicians.

Navenibart Phase 3 Clinical Trial Overview

Trial Name	NCT ID	Design	Population	Primary Completion
ALPHA-ORBIT	NCT06842823	Randomized, double-blind, placebo-controlled	Adults and adolescents (12+) with HAE Type 1/2	March 2027
ORBIT-EXPANSE	NCT07204938	Long-term extension, two-part design	ALPHA-ORBIT completers	June 2031

What is hereditary angioedema (HAE)?

Hereditary angioedema (HAE) is a rare genetic disorder. It causes recurrent, unpredictable swelling attacks. These episodes can affect the skin, gastrointestinal tract, and airways. Airway swelling poses life-threatening risks.

The disease stems from mutations in the SERPING1 gene. This gene encodes C1 esterase inhibitor (C1-INH). When C1-INH is deficient or dysfunctional, the plasma kallikrein-kinin system becomes overactive. Uncontrolled plasma kallikrein generates excess bradykinin. Bradykinin increases vascular permeability, causing the characteristic swelling.

HAE affects approximately 1 in 50,000 people worldwide. The condition has three main types:

• Type 1: Low C1-INH levels (most common, ~85% of cases)
• Type 2: Normal or elevated C1-INH levels but dysfunctional protein
• Type 3: Normal C1-INH levels with mutations in Factor XII gene (rare)

Current treatments include plasma-derived and recombinant C1-INH concentrates, bradykinin receptor antagonists, and plasma kallikrein inhibitors. The FDA maintains a list of approved HAE therapies. Patients can also learn more about rare disease treatment advances in our dedicated resource center.

When will Navenibart reach the market?

BioCryst has guided for a regulatory filing by the end of 2027. This timeline depends on positive Phase 3 results from the ALPHA-ORBIT trial. The study's primary completion in March 2027 will trigger data analysis and package preparation.

European approval would follow the standard EMA centralized procedure. Neopharmed Gentili would then handle commercial launch activities across EU member states. U.S. filing would proceed separately under BioCryst's control. The dual-track approach maximizes optionality for both markets.

Frequently Asked Questions

Primary Sources

1. SEC Form 8-K (May 4, 2026) — BioCryst Navenibart European Licensing Agreement disclosure
2. SEC Form 8-K (October 14, 2025) — BioCryst Astria Therapeutics Merger Agreement
3. ClinicalTrials.gov NCT06842823 — ALPHA-ORBIT: Phase 3 Study of Navenibart in HAE
4. ClinicalTrials.gov NCT07204938 — ORBIT-EXPANSE: Long-Term Safety Study of Navenibart
5. FDA.gov — Hereditary Angioedema (HAE) Approved Products

Related Coverage

• Heart Failure 2026: Vutrisiran Data & European Pharma News
• Rare Disease Resource Center
• BioCryst Pharmaceuticals Company Profile